Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | XDH | P47989 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16147172 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2KMT2AMEN1TP53CYP1A2 | |
| SCHEMBL16146121 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2KMT2AMEN1TP53CYP1A2 | |
| SCHEMBL16146497 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2KMT2AMEN1TP53CYP1A2 | |
| SCHEMBL16146349 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2KMT2AMEN1TP53CYP1A2 | |
| SCHEMBL16146106 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2KMT2AMEN1TP53CYP1A2 | |
| SCHEMBL16146155 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2KMT2AMEN1TP53CYP1A2 | |
| SCHEMBL16145964 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2KMT2AMEN1TP53CYP1A2 | |
| SCHEMBL16146914 | 0.84 | SMN1; SMN2 (0.72) | SMN1; SMN2KMT2AMEN1TP53CYP1A2 | |
| SCHEMBL30516792 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2KMT2AMEN1TP53CYP1A2 | |
| SCHEMBL16146129 | 0.82 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AMEN1TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475445-B1 | MEANS AND METHODS FOR TREATING PARKINSON'S DISEASE | UNIV LUXEMBOURG (LU) | 2022-02-09 | — | — | EP | claimed |
| US-20190324017-A1 | MEANS AND METHODS FOR TREATING PARKINSON'S DISEASE | UNIVERSITE DU LUXEMBOURG (LU) | 2019-10-24 | — | — | US | claimed |
| EP-3475445-A1 | MEANS AND METHODS FOR TREATING PARKINSON'S DISEASE | Université du Luxembourg (LU) | 2019-05-01 | — | — | EP | claimed |
| WO-2017220315-A1 | MEANS AND METHODS FOR TREATING PARKINSON'S DISEASE | UNIVERSITE DU LUXEMBOURG (LU) | 2017-12-28 | — | — | WO | claimed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| EP-3583951-B1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | UNIV KYOTO (JP) | 2026-03-25 | — | — | EP | disclosed |
| US-20250346601-A1 | HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND THERAPY OF CIRCADIAN RHYTHM DISORDERS | UNIV PALACKEHO (CZ) | 2025-11-13 | — | — | US | disclosed |
| EP-4532498-B1 | HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND THERAPY OF CIRCADIAN RHYTHM DISORDERS | UNIV PALACKEHO (CZ) | 2025-10-29 | — | — | EP | disclosed |
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | KYOTO UNIVERSITY (JP) | 2024-07-02 | — | — | US | disclosed |
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | KYOTO UNIVERSITY (JP) | 2024-07-02 | — | — | US | disclosed |
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | KYOTO UNIVERSITY (JP) | 2024-07-02 | — | — | US | disclosed |
| EP-4333851-A1 | CORRECTION OF EXON SKIPPING IN MONOCYTE-DERIVED CELLS FOR IMPROVED IMMUNE RESPONSE | Schelling, D. Christopher (US) | 2024-03-13 | — | — | EP | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| US-9879014-B2 | Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease | KYOTO UNIVERSITY (JP) | 2018-01-30 | — | — | US | disclosed |
| WO-2017220315-A1 | MEANS AND METHODS FOR TREATING PARKINSON'S DISEASE | UNIVERSITE DU LUXEMBOURG (LU) | 2017-12-28 | — | — | WO | disclosed |
| WO-2016115434-A1 | COMPOUNDS FOR IMPROVING MRNA SPLICING | THE GENERAL HOSPITAL CORPORATION (US) | 2016-07-21 | — | — | WO | disclosed |
| US-20160152620-A1 | METHOD FOR SCREENING SUBSTANCE CAPABLE OF INHIBITING ABNORMAL SPLICING CAUSATIVE OF ONSET OR PROGRESS OF DISEASE | KYOTO UNIVERSITY (JP) | 2016-06-02 | — | — | US | disclosed |
| EP-3020829-A1 | METHOD FOR SCREENING SUBSTANCE CAPABLE OF INHIBITING ABNORMAL SPLICING CAUSATIVE OF ONSET OR PROGRESS OF DISEASE | Kyoto University (JP) | 2016-05-18 | — | — | EP | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
| WO-2010118367-A2 | ANTIVIRAL PYRIMIDINES | PROGENICS PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346601-A1 | HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND THERAPY OF CIRCADIAN RHYTHM DISORDERS | CRY1, PER2, CRY2 | SMN1; SMN2 2604/4885KMT2A 1002/4885MEN1 1250/4885 |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | SMN1; SMN2 2822/4885KMT2A 3050/4885MEN1 3276/4885 |
| US-20160152620-A1 | METHOD FOR SCREENING SUBSTANCE CAPABLE OF INHIBITING ABNORMAL SPLICING CAUSATIVE OF ONSET OR PROGRESS OF DISEASE | RBM17, SNRPE, RBM22 | SMN1; SMN2 47/4885KMT2A 3845/4885MEN1 3517/4885 |
| US-20190324017-A1 | MEANS AND METHODS FOR TREATING PARKINSON'S DISEASE | PARK7, SNCA, PINK1 | SMN1; SMN2 11/4885KMT2A 2446/4885MEN1 4463/4885 |
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | RBM17, SFPQ, HNRNPAB | SMN1; SMN2 37/4885KMT2A 3468/4885MEN1 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.